{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:13:09Z","timestamp":1783944789220,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102591","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:03:22Z","timestamp":1780329802000},"page":"102591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7432-1282","authenticated-orcid":false,"given":"Nancy","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7268-5077","authenticated-orcid":false,"given":"Miguel","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimki","family":"Haloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9430-5722","authenticated-orcid":false,"given":"Yalda","family":"Nikanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad Bonakdar","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2836","authenticated-orcid":false,"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clgc.2026.102591_bib0001","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.23.00723","article-title":"Early treatment intensification in metastatic hormone-sensitive prostate cancer","volume":"41","author":"Wala","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2026.102591_bib0002","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102591_bib0003","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102591_bib0004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eururo.2024.04.026","article-title":"The role of microsatellite instability\/DNA mismatch repair deficiency and tumor mutational burden as biomarkers in predicting response to immunotherapy in castration-resistant prostate cancer","volume":"86","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102591_bib0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2020.12.039","article-title":"Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians","volume":"79","author":"Merseburger","year":"2021","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.clgc.2026.102591_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17183048","article-title":"Evolution of potentially actionable genomic alterations in advanced prostate cancer: a real-world analysis of serial circulating tumor DNA testing","volume":"17","author":"Muniz","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2026.102591_bib0007","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.2023.41.6_suppl.239","article-title":"Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC)","volume":"41","author":"Childs","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102591_bib0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/cancers17030480","article-title":"Evaluating tumour mutational burden as a key biomarker in personalized cancer immunotherapy: a pan-cancer systematic review","volume":"17","author":"Zgura","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.clgc.2026.102591_bib0009","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1158\/1078-0432.CCR-20-0458","article-title":"Tumor mutational burden, toxicity, and response of Immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis","volume":"26","author":"Osipov","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clgc.2026.102591_bib0010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102591_bib0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13073-021-00979-8","article-title":"Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers","volume":"13","author":"Pham","year":"2021","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102591_bib0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13014-025-02711-x","article-title":"Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair","volume":"20","author":"Liu","year":"2025","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clgc.2026.102591_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.radonc.2020.10.020","article-title":"Identification of the mutation signature of the cancer genome caused by irradiation","volume":"155","author":"Kageyama","year":"2021","journal-title":"Radiother Oncol"},{"issue":"10467","key":"10.1016\/j.clgc.2026.102591_bib0014","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clgc.2026.102591_bib0015","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clgc.2026.102591_bib0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102591_bib0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1078-0432.CCR-25-2750","article-title":"Additive clinical utility of microsatellite instability and tumor mutational burden to predict immune checkpoint inhibitor effectiveness in metastatic castration-resistant prostate cancer","volume":"32","author":"Sayegh","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.clgc.2026.102591_bib0018","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2026.102591_bib0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/oncolo\/oyab064","article-title":"Discordance in tumor mutation burden from blood and tissue affects association with response to immune checkpoint inhibition in real-world settings","volume":"27","author":"Sturgill","year":"2022","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:52:32Z","timestamp":1783943552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000911"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102591","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102591"}}